The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis
作者： Bebeka Gjoksi , Chafik Ghayor , Barbara Siegenthaler , Nisarat Ruangsawasdi , Marcy Zenobi-Wong
DOI: 10.1016/J.BONE.2015.05.004
关键词:
摘要: Currently, there are several treatments for osteoporosis however; they all display some sort of limitation and/or side effects making the need new imperative. We have previously demonstrated that NMP is a bioactive drug which enhances bone regeneration in vivo and acts as an enhancer morphogenetic protein (BMP) vitro. also inhibits osteoclast differentiation attenuates resorption. In present study, we tested bromodomain inhibitor prevention on ovariectomized (OVX) induced rats while treated systemically with NMP. Female Sprague-Dawley were weekly treatment was administrated 1 week after surgery 15 weeks. Bone parameters related serum biomarkers analyzed. weeks decreased ovariectomy-induced gained weight average by 43% improved mineral density (BMD) volume over total (BV/TV) rat femur 25% 41% respectively. Moreover, apposition rate turnover group at similar levels those Sham group. Due to function low affinity its mechanism action involving osteoblasts/osteoclasts balance inhibitory effect inflammatory cytokines, promising therapeutic compound osteoporosis.
core.ac.uk
uzh.ch
elsevier.com
sci-hub.se 参考文章(46)
J. Chris Gallagher, A.J. Sai, Molecular biology of bone remodeling: Implications for new therapeutic targets for osteoporosis Maturitas. ,vol. 65, pp. 301- 307 ,(2010) , 10.1016/J.MATURITAS.2010.01.002
R. J. Hollick, D. M. Reid, Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause International. ,vol. 17, pp. 66- 72 ,(2011) , 10.1258/MI.2011.011014
R.K. Prinjha, J. Witherington, K. Lee, Place your BETs: the therapeutic potential of bromodomains Trends in Pharmacological Sciences. ,vol. 33, pp. 146- 153 ,(2012) , 10.1016/J.TIPS.2011.12.002
Gerda Egger, Gangning Liang, Ana Aparicio, Peter A. Jones, Epigenetics in human disease and prospects for epigenetic therapy Nature. ,vol. 429, pp. 457- 463 ,(2004) , 10.1038/NATURE02625
François Lamoureux, Marc Baud’huin, Lidia Rodriguez Calleja, Camille Jacques, Martine Berreur, Françoise Rédini, Fernando Lecanda, James E. Bradner, Dominique Heymann, Benjamin Ory, Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nature Communications. ,vol. 5, pp. 3511- ,(2014) , 10.1038/NCOMMS4511
RUSSELL T. TURNER, B. LAWRENCE RIGGS, THOMAS C. SPELSBERG, Skeletal Effects of Estrogen Endocrine Reviews. ,vol. 15, pp. 275- 300 ,(1994) , 10.1210/EDRV-15-3-275
Mary L. Bouxsein, Mechanisms of osteoporosis therapy: a bone strength perspective. Clinical Cornerstone. ,vol. 5, ,(2003) , 10.1016/S1098-3597(03)90043-3
Martin Philpott, Jing Yang, Tony Tumber, Oleg Fedorov, Sagar Uttarkar, Panagis Filippakopoulos, Sarah Picaud, Tracy Keates, Ildiko Felletar, Alessio Ciulli, Stefan Knapp, Tom D. Heightman, Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery Molecular BioSystems. ,vol. 7, pp. 2899- 2908 ,(2011) , 10.1039/C1MB05099K
Julie M Joyner, Louise J Hutley, Donald P Cameron, Estrogen receptors in human preadipocytes Endocrine. ,vol. 15, pp. 225- 230 ,(2001) , 10.1385/ENDO:15:2:225
Jake Shortt, Andy K Hsu, Benjamin P Martin, Karen Doggett, Geoffrey M Matthews, Maria A Doyle, Jason Ellul, Tina E Jockel, Daniel M Andrews, Simon J Hogg, Andrea Reitsma, David Faulkner, P Leif Bergsagel, Marta Chesi, Joan K Heath, William A Denny, Philip E Thompson, Paul J Neeson, David S Ritchie, Grant A McArthur, Ricky W Johnstone, None, The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound Cell Reports. ,vol. 7, pp. 1009- 1019 ,(2014) , 10.1016/J.CELREP.2014.04.008